On November 17, 2025, Imbria Pharmaceuticals, a clinical-stage company developing transformational cardiovascular disease therapeutics, announced the participation of AXA IM Alts in an upsized Series B financing. With this investment, AXA IM Alts joins a leading investor syndicate that includes RA Capital, SV Health Investors, Deep Track Capital, AN Ventures, Catalio Capital Management, and Cytokinetics. Wilson Sonsini Goodrich & Rosati advised AXA IM Alts on patent matters related to the transaction.

Proceeds from the financing will support the continued clinical development of ninerafaxstat, Imbria’s differentiated, first-in-class therapy designed to improve cardiac energetics in patients with serious cardiovascular diseases.

The Wilson Sonsini team that advised AXA IM Alts on patent matters related to the transaction was led by Valentin Zunic and included Michael Hostetler and Kaia Parenti.

For more information, please see Imbria Pharmaceuticals’ news release.